Stay updated on Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial

Sign up to get notified when there's something new on the Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the study details related to reducing serum HBsAg levels in patients with HBsAg+ advanced stage HCC through immune checkpoint therapy vs. target therapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:06.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as being HBsAg positive, age 18 or older, and having a documented diagnosis of HCC. Previously, this section had no information provided.
    Difference
    43%
    Check dated 2024-05-22T21:02:02.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:14:15.000Z thumbnail image

Stay in the know with updates to Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immune Checkpoint vs Target Therapy for HBsAg+ HCC Clinical Trial page.